Shares of Myriad Genetics, Inc. (NASDAQ:MYGN) have been assigned a consensus recommendation of “Hold” from the seventeen brokerages that are currently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $22.25.

A number of brokerages have recently commented on MYGN. Piper Jaffray Companies reissued a “hold” rating and issued a $22.00 price target on shares of Myriad Genetics in a report on Friday, July 14th. BidaskClub lowered shares of Myriad Genetics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Jefferies Group LLC reaffirmed a “hold” rating and set a $21.00 target price (up previously from $18.00) on shares of Myriad Genetics in a report on Wednesday, May 3rd. Zacks Investment Research raised shares of Myriad Genetics from a “hold” rating to a “buy” rating and set a $28.00 target price on the stock in a report on Monday, July 17th. Finally, Cowen and Company reaffirmed a “hold” rating and set a $25.00 target price on shares of Myriad Genetics in a report on Friday, July 14th.

Shares of Myriad Genetics (NASDAQ:MYGN) remained flat at $24.16 on Friday. The company had a trading volume of 819,313 shares. The firm has a market capitalization of $1.65 billion, a PE ratio of 51.62 and a beta of 0.32. The stock has a 50 day moving average price of $24.48 and a 200 day moving average price of $20.14. Myriad Genetics has a one year low of $15.15 and a one year high of $32.54.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings results on Tuesday, May 2nd. The company reported $0.27 EPS for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.03. The firm had revenue of $196.90 million for the quarter, compared to analyst estimates of $188.89 million. Myriad Genetics had a net margin of 4.26% and a return on equity of 10.53%. Equities research analysts predict that Myriad Genetics will post $1.01 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the company. BlackRock Inc. boosted its stake in Myriad Genetics by 168,335.7% in the first quarter. BlackRock Inc. now owns 9,541,884 shares of the company’s stock valued at $183,203,000 after buying an additional 9,536,219 shares in the last quarter. Vanguard Group Inc. boosted its stake in Myriad Genetics by 16.8% in the first quarter. Vanguard Group Inc. now owns 6,251,030 shares of the company’s stock valued at $120,020,000 after buying an additional 897,287 shares in the last quarter. Camber Capital Management LLC boosted its stake in Myriad Genetics by 6.5% in the first quarter. Camber Capital Management LLC now owns 4,325,000 shares of the company’s stock valued at $83,040,000 after buying an additional 265,000 shares in the last quarter. Frontier Capital Management Co. LLC boosted its stake in Myriad Genetics by 1.4% in the first quarter. Frontier Capital Management Co. LLC now owns 3,075,954 shares of the company’s stock valued at $59,058,000 after buying an additional 41,432 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Myriad Genetics by 59.7% in the first quarter. Dimensional Fund Advisors LP now owns 2,642,820 shares of the company’s stock valued at $50,742,000 after buying an additional 987,966 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: “Analysts Set Myriad Genetics, Inc. (MYGN) PT at $22.25” was originally published by Daily Political and is the property of of Daily Political. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.dailypolitical.com/2017/07/24/analysts-set-myriad-genetics-inc-mygn-pt-at-22-25.html.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Analyst Recommendations for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.